Follow us on Bluesky
Bluesky · Hashtag

#$LLY

51
posts · 30d
20
users
2
posts / day
2.5
posts / user
-14% vs last week

#$LLY is an active hashtag on Bluesky. In the last 30 days, 20 people shared 51 posts with it — around 2 a day. Activity is down 14% versus the previous week, peaking on Sep 22 with 6 posts.

#$LLY posts per day (last 30 days)

Related tags

Tags most often used together with #$LLY.

#$NVO 7 #$GSK 5 #$MRK 5 #Zepbound 5

Posts with #$LLY

Carl Quintanilla
@carlquintanilla.bsky.social
3 months ago
“.. given the patient demographics and the unusual nature of the application, STAT asked the White House whether the patient was President Trump ..” $LLY

EXCLUSIVE: Eli Lilly gave compassionate use access to retatrutide, their unapproved powerful obesity drug, to a 79-year-old man in April. The application was arranged by a top doctor at NIH, and cleared by the FDA. www.statnews.com/2026/06/23/e...

www.statnews.com
19 87 255
Quantian
@quantian.bsky.social
4 months ago
Napkin math on $LLY retatrutide P3 top line readout implies (full results forthcoming) the drug has a 99.5% efficacy rate and a 2.75σ effect size vs placebo. Not quite perfect separation between control and experimental arm like in the P2, but among the most successful drug trials in history.
7 18 140
Nancy Levine Stearns
@nancylevinestearns.bsky.social
3 months ago
Lilly CEO Dave Ricks announced that Lilly is a proud participant in Trump’s Freedom 250, the White House-backed hijack of America’s birthday. What is Lilly’s message about Trump’s war on science? #Science $LLY
8 22 56
midgardfinance.com
@midgardfinance.com
1 day ago
💉 #obesity 🇩🇰 Novo Nordisk's #CagriSema beat 🇺🇸 Eli Lilly's tirzepatide in REIMAGINE 5: 12.4% against 9.1% weight loss at 60 weeks in type 2 diabetes. At 1.0/1.0 mg, against tirzepatide's lowest 5 mg. The three head-to-heads fought at top dose all went to Lilly. $NOVO $LLY
Horizontal bar chart of the four head-to-head trials that put a Novo Nordisk incretin against an Eli Lilly one, oldest readout at the top, weight loss at the primary endpoint on a scale from zero to about 34 per cent. Each trial has two bars, the Novo arm in blue above the Lilly arm in red, and each bar is labelled with the drug, its dose and its result. Each row also says whether the arms were at their top dose. SURMOUNT-5, obesity, 72 weeks, 2025, won by Lilly, both at top dose in 2025: semaglutide 2.4 mg 13.7 per cent against tirzepatide 15 mg 20.2 per cent. REDEFINE 4, obesity, 84 weeks, February 2026, won by Lilly, both at top dose: CagriSema 2.4/2.4 mg 23.0 per cent against tirzepatide 15 mg 25.5 per cent. ACHIEVE-3, type 2 diabetes, 52 weeks, March 2026, won by Lilly, both at top dose: oral semaglutide 14 mg 5.3 per cent against orforglipron 36 mg 8.2 per cent. REIMAGINE 5, type 2 diabetes, 60 weeks, September 2026, won by Novo, neither at top dose: CagriSema 1.0/1.0 mg 12.4 per cent against tirzepatide 5 mg 9.1 per cent, the only row where the blue bar is longer than the red one.
0 2 3
George Pearkes
@peark.es
8 months ago
$LLY also guiding material price declines but guidance handily topped estimates. Orforglipron is their oral GLP-1. *ELI LILLY SEES 2026 REV. $80B TO $83B, EST. $77.71B *ELI LILLY SEES GLOBAL PRICING DECLINE IN LOW- TO MID-TEENS *LILLY EXPECTS ORFORGLIPRON U.S. LAUNCH IN 2Q, PENDING FDA NOD

OOF $NVO
2025 YEAR RESULTS • Sales DKK309.06 billion, estimate DKK307.62 billion (Bloomberg Consensus) • Ebit DKK127.66 billion, estimate DKK129.56 billion • Net income DKK102.43 billion, estimate DKK103.31 billion • EPS DKK23.03, estimate DKK23.28 YEAR FORECAST • Sees sales at constant exchange rates - 5% to -13%, estimate -1.39% • Sees operating profit at constant FX -5% to - 13%, estimate - 3.12%
3 3 21
Nancy Levine Stearns
@nancylevinestearns.bsky.social
3 months ago
Union of Concerned Scientists: "Last week, the White House released draft regulations that—if enacted—will upend US science as we know it." How does Lilly reconcile is proud participation in Trump's Freedom 250 with Trump's war on science? #Science $LLY blog.ucs.org/alexa-dietri...
The Trump Administration Has Launched Its Biggest Threat Yet to Scientific Research. We Can Stop Them.

blog.ucs.org

The Trump Administration Has Launched Its Biggest Threat Yet to Scientific Research. We Can Stop Them.

This proposed rule is about one thing: the Trump administration’s hunger to exert control over the federal scientific enterprise and re-direct it toward their own political agenda. It's an attack on s...
2 8 21
MarketPlays
@marketplays.com
2 days ago
$NVO is getting hit after its investor day. Management pitched 5-plus blockbusters by 2030 and about $23B in pipeline sales by 2035. Traders wanted a sharper plan versus $LLY and more detail on the 2032 patent cliff. Shares were down as much as 7%-9%.
0 0 1
Lou Mannheim
@loumannheim87.bsky.social
about 2 months ago
$LLY $NVO ... Barrons with a cover story on GLP1 drugs. Race to see who makes a bigger contribution to humanity-- GLP1 or AI
3 0 10

Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.

View all posts on Bluesky

Explore trending tags

#art #oc #nsfw #furry #digitalart #fanart #furryart #AI #photography #gay #illustration #fcf
Back to all tags